(QGEN) Qiagen - Ratings and Ratios

Qiagen N.V., a global leader in molecular biology solutions, specializes in transforming biological samples into actionable molecular insights. Headquartered in Venlo, Netherlands, the company was founded in 1984 and is listed on the NYSE under the ticker symbol QGEN. Qiagen operates across various sectors, including molecular diagnostics, academia, pharmaceuticals, and applied testing. Its extensive product portfolio encompasses primary and secondary sample technology consumables, such as nucleic acid stabilization, purification kits, and magnetic bead technologies. The company also offers instruments for nucleic acid purification, quality control, and accessories, along with immune response consumables like TB testing kits and assays for post-transplant monitoring. Additionally, Qiagen provides oncology-related assays for prenatal testing and HPV detection, as well as integrated PCR solutions and digital PCR instruments. Its offerings extend to NGS gene panels, library prep kits, and bioinformatics solutions. The company also delivers custom laboratory and genomic services and software-as-a-service solutions.

Qiagens technical indicators suggest a mixed outlook. The stocks last price of $42.32 is above its 20-day SMA of $40.56 but below its 200-day SMA of $43.09, indicating potential short-term weakness. The ATR of 1.16 reflects moderate volatility. Fundamental analysis reveals a market cap of $9.07 billion, with a high P/E ratio of 110.47, though the forward P/E of 17.61 signals anticipated earnings growth. The P/B ratio of 2.54 and P/S of 4.59 indicate a premium valuation, while the RoE of 2.34 suggests modest profitability. Over the next three months, the stock may face headwinds from its elevated P/E ratio, but its expanding product lines and strong market position could support growth.